company overview M A R C H

Size: px

Start display at page:

Download "company overview M A R C H"

Gary Hood
6 years ago
Views:

1 company overview MARCH 2016

2 our focus INNOVATION in Aesthetics and Dermatology DISCOVERY CLINICAL DEVELOPMENT COMMERCIALIZATION 2 / CONFIDENTIAL and PROPRIETARY

3 the sienna opportunity CLEAR STRATEGY for building pipeline of early to late stage novel assets EXCEPTIONAL TEAM with a track record of success across leading global brands UNIQUELY FOCUSED on developing aesthetic and dermatology products that will change the practice of medicine BUILD MULTI-ASSET PIPELINE first asset secured 3 / CONFIDENTIAL and PROPRIETARY

sienna s vision to build a leading aesthetic company Long-term strategy Founding vision! Apply high scientific rigor to aesthetics and dermatology!

Develop and commercialize Silver Plasmonic Therapy (SPT) for light hair removal and acne! Maximize the value of SPT platform through expansion in new indications!

4 sienna s vision to build a leading aesthetic company Long-term strategy Founding vision! Apply high scientific rigor to aesthetics and dermatology! Develop and commercialize innovative products that add value to patients and physician s practice Near-term execution! Develop and commercialize Silver Plasmonic Therapy (SPT) for light hair removal and acne! Maximize the value of SPT platform through expansion in new indications! Aggressively expand product portfolio / pipeline! Leverage world-class team s experience in aesthetics and dermatology! Build a leading portfolio! Establish commercial leadership with Dermatologists, Plastic Surgeons, and Core Aesthetic Physicians 4 / CONFIDENTIAL and PROPRIETARY

5 clear strategy for building our pipeline SCIENCE Innovative breakthroughs MARKET Aesthetics and Dermatology COMMERCIAL OPPORTUNITIES Minimum $250 - $500M peak sales per product Develop a Comprehensive Pipeline of Early to Late Stage Novel Assets REIMBURSEMENT Self pay and reimbursed 5 / CONFIDENTIAL and PROPRIETARY

6 our vision: bring innovative products to market which change the practice of medicine AESTHETIC AND DERMATOLOGY TARGETS CONTOURING SKIN REJUVENATION HAIR REMOVAL and GROWTH ACNE/ ROSACEA ATOPIC DERMATITIS PSORIASIS AESTHETIC DERMATOLOGY 6 / CONFIDENTIAL and PROPRIETARY

leading team in aesthetic and medical dermatology Frederick C.

Officer Former VP and Head of Dermatology and Aesthetics R&D

Smither Chief Financial Officer Former Chief Financial Officer

Lizzul MD, PhD Chief Medical Officer Former Sr.

Director Clinical Research, Dermatology Todd Harris PhD President

Former Manager Former NIH Fellow and Doctoral Student Diane

Quality Former VP of Regulatory Affairs, PV, and Research

Head of Research Jere Fellmann PhD Head of Development Operations

President, Operations Ted Schwarz Head of Global Strategic

Discovery and Molecular Biology Former VP Clinical Operations

Development Lead Former VP Human Resources Former VP Human Resource

7 leading team in aesthetic and medical dermatology Frederick C. Beddingfield III MD, PhD President and CEO Former Chief Medical Officer Former VP and Head of Dermatology and Aesthetics R&D Associate Clinical Professor of Dermatology John W. Smither Chief Financial Officer Former Chief Financial Officer Former VP of Finance and Administration Paul F. Lizzul MD, PhD Chief Medical Officer Former Sr. Medical Director Former Assoc. Director Clinical Research, Dermatology Todd Harris PhD President of Sienna Labs and Head of Corporate Development Founder & CEO Former Manager Former NIH Fellow and Doctoral Student Diane Stroehmann MS, RAC Chief of Staff and Head of Regulatory Affairs & Quality Former VP of Regulatory Affairs, PV, and Research Compliance Former Head of Regulatory Affairs Serge Lichtsteiner PhD Head of Research Jere Fellmann PhD Head of Development Operations Susan Lundeen Vice President, Human Resources Majed Kheir MBA Vice President, Operations Ted Schwarz Head of Global Strategic Marketing Former Vice President of Research Former Director, Lead Discovery and Molecular Biology Former VP Clinical Operations Former Director of Clinical Affairs and PRIALT WW Program Development Lead Former VP Human Resources Former VP Human Resource and Administration Former Executive Dir. Supply Chain and Planning Former Director Operations Strategic Planning Former President Former President Former Director of Global Marketing & Business Development 7 / CONFIDENTIAL and PROPRIETARY

8 strong board Keith Leonard Former CEO, Kythera Co-Founder, Managing Director, ARCH Venture Partners Bob More MBA Todd Harris PhD Executive Chairman Chairman, One Revolution 8 Robert Nelsen / CONFIDENTIAL and PROPRIETARY Founder and President Sienna Labs, Head of Corporate Development, Sienna Biopharmaceuticals Kristina Burow Managing Director, ARCH Venture Partners Frederick C. Beddingfield III MD, PhD Co-Founder, President and CEO Sienna Biopharmaceuticals

9 this team has developed top brands FROM DISCOVERY TO COMMERCIALIZATION AT GLOBAL COMPANIES AESTHETIC PRODUCTS DERMATOLOGY PRODUCTS 9 / CONFIDENTIAL and PROPRIETARY

10 team s demonstrated success commercializing new scientific breakthroughs 65+ PRODUCTS WORKED ON 100 INTERNATIONAL REGULATORY FILINGS AND APPROVALS FOR VARIOUS INDICATIONS 6 FDA ADVISORY COMMITTEES 17 FDA APPROVALS 10 / CONFIDENTIAL and PROPRIETARY

11 track record of driving meaningful value Unanimous FDA Advisory Committee (17-0) KYBELLA (U.S.) and BELKYRA (Canada) Regulatory Approvals KYTH-105 (setipiprant) In-licensing and IND Acceptance 11 / CONFIDENTIAL and PROPRIETARY

12 silver plasmonic therapy OVERVIEW UNMET NEEDS MARKET STATUS Breakthrough technology: silver plasmonic therapy Based on the science of plasmonic resonance Secured through Sienna Labs Light hair removal Acne Potential for skin rejuvenation Works with current existing base of energy devices Expands populations who are candidates for treatment Clinical proof-of-concept: Prolonged efficacy Favorable safety profile Aggressive and expanding IP portfolio: 9 issued patents 20+ patents pending Aesthetic product which benefits doctor and patients and a clear regulatory pathway for approval Class II device 510(k) clearance 12 / CONFIDENTIAL and PROPRIETARY

13 what are plasmonic particles? ULTRA EFFICIENT, NEAR INFRARED LIGHT ABSORBING SILVER BASED PARTICLES Near-IR Light E-field Heat Oscillations of Electrons Contained in a topical pre-treatment solution Activation by a pulse of laser light causes a burst of energy Energy thermally changes the sebaceous glands and pores Particles do not penetrate through the epithelial barriers 13 / CONFIDENTIAL and PROPRIETARY

Pilosebaceous Unit and Activated with Light CLINICAL RESULT Selective Restructuring of Pilosebaceous Unit Hair: Permanent

14 an innovative mechanism of action DARK HAIR REMOVAL by Selective Photothermolysis Near-IR Light OVERVIEW LIGHT HAIR REMOVAL with Silver Plasmonic Therapy Near-IR Light Thermal Injury Zone Plasmonic Particles Delivered to the Pilosebaceous Unit and Activated with Light CLINICAL RESULT Selective Restructuring of Pilosebaceous Unit Hair: Permanent reduction in terminal hair counts including light-pigmented hair Acne: Prolonged reduction in acne lesions 14 / CONFIDENTIAL and PROPRIETARY

15 large, unmet needs SILVER PLASMONIC THERAPY LIGHT HAIR REMOVAL No Effective Solution ACNE Lack of Effective Procedural Solutions $2B+ procedure market 1 6M procedure opportunity 4 $3B+ prescription market 2 7M procedure opportunity 4 $250M - $500M PEAK YEAR OPPORTUNITY PER INDICATION 1. Medical Insight Inc., 2. IMS Data, 3. ASAPS 2014, 4. company market research and analysis 15 / CONFIDENTIAL and PROPRIETARY

opportunities for expansion with SPT Existing laser hair removal

away AND acne sufferers seeking treatment from Derms Potential for

hair types Potential for other future indications: Rosacea Sebaceous

16 opportunities for expansion with SPT Existing laser hair removal consumers with light / mixed hair Light hair consumers being turned away AND acne sufferers seeking treatment from Derms Potential for expansion in hair removal: Darker skin Increased efficacy in all hair types Potential for other future indications: Rosacea Sebaceous gland hyperplasia Keratosis Pyloris $ Time 16 / CONFIDENTIAL and PROPRIETARY

17 INNOVATION in Aesthetics and Dermatology CLEAR STRATEGY EXCEPTIONAL TEAM UNIQUE FOCUS DEVELOPING PIPELINE 17 / CONFIDENTIAL and PROPRIETARY

Company Overview. August 2018

Company Overview. August 2018 Company Overview August 2018 Forward Looking Statements This presentation contains forward-looking statements. All statements other than descriptions of historical facts contained in this presentation,